---
title: "Hot Pre-Market Trades in US Stocks: Veritone Down 17.71%; Moderna Down 3.36%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300680230.md"
description: "Veritone down 17.71% in pre-market trading; Moderna down 3.36%; Socket Mobile up 46.56%; DataMeds AI up 39.13%; Generation Income Properties up 28.72%"
datetime: "2026-10-01T11:52:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300680230.md)
  - [en](https://longbridge.com/en/news/300680230.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300680230.md)
generator: "portal-rs"
---

# Hot Pre-Market Trades in US Stocks: Veritone Down 17.71%; Moderna Down 3.36%

**Hot Pre-Market Trades in US Stocks**

Veritone is down 17.71% in pre-market trading. Veritone is down 17.71% in pre-market trading. No significant news recently; trading is active with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons require further observation. no\_news

Moderna is down 3.36% in pre-market trading. Based on recent key news:

1.  On September 30, Citigroup downgraded Moderna's rating from "Neutral" to "Sell," citing overvaluation. This move caused Moderna's stock price to fall 6.2% in pre-market trading. Source: Zhitong Finance

2.  On September 29, Moderna's stock price hit a 52-week high as its mRNA neoantigen therapy research in collaboration with Merck & Co. attracted market attention. However, analysts pointed out valuation risks, with a target price of only around $77. Source: Wall Street News

3.  On September 30, analysts noted that Moderna's recent sharp stock price increase has already reflected overly optimistic expectations, suggesting investors consider exiting. Source: Barron’s The biotechnology sector has recently shown volatile performance, with increased valuation risks.

**Top Gainers in US Pre-Market Trading**

Socket Mobile is up 46.56% in pre-market trading, with no significant recent news. Trading is active with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons require further observation.

DataMeds AI is up 39.13% in pre-market trading. Based on recent key news:

1.  On September 29, DataMeds AI launched the "Health Lives Here" mobile health app, partnering with Tollo Health and the NFL Alumni Association to integrate telemedicine, pharmacy dispensing, wearable device data, and AI health coaching, focusing on services for GLP-1 patients. This move pushed the company's stock price up more than 22% during regular trading hours.

2.  On September 28, the company mentioned several risk factors in its latest annual report, cautioning investors to treat forward-looking statements with care, which may create uncertainty affecting the stock price.

3.  On October 1, DataMeds AI issued a press release via ACCESS Newswire, emphasizing the company's responsibility for information, further boosting market confidence in its transparency. Innovation in the health technology sector is accelerating, drawing increased market attention.

Generation Income Properties is up 28.72% in pre-market trading. Based on recent news,

1.  On October 1, Lion Group Holding Ltd announced a strategic reallocation of part of its digital asset portfolio, causing its stock price to fall 15.4% in pre-market trading.

2.  On October 1, CLPS Inc fell 14.4% in pre-market trading.

3.  On October 1, Akso Health Group fell 14% in pre-market trading. Recent market volatility has been significant, requiring attention to macroeconomic developments.

### Related Stocks

- [VERI.US](https://longbridge.com/en/quote/VERI.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [SCKT.US](https://longbridge.com/en/quote/SCKT.US.md)
- [MEDS.US](https://longbridge.com/en/quote/MEDS.US.md)
- [GIPR.US](https://longbridge.com/en/quote/GIPR.US.md)

## Related News & Research

- [Moderna Stock Is Trending: What's Going On?](https://longbridge.com/en/news/300713446.md)
- [CPHI 2026: Moderna builds on its COVID-era manufacturing lessons](https://longbridge.com/en/news/301156866.md)
- [Tempus expands multi-year collaboration with Moderna, Merck on V940 melanoma vaccine commercialization support](https://longbridge.com/en/news/301144495.md)
- [Moderna loses US government license defense in Northwestern patent case](https://longbridge.com/en/news/300701587.md)
- [Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations "Unrealistic"](https://longbridge.com/en/news/300564590.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**